Displaying drugs 10301 - 10325 of 12494 in total
Baicalein
Baicalein is under investigation in clinical trial NCT03830684 (A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever).
Investigational
Matched Description: … Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever). ... Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of …
Dianexin
Dianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients).
Investigational
Matched Description: … Dianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin …
Terevalefim
Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Investigational
Matched Description: … of a Deceased Donor Kidney). ... Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients …
Etavopivat
Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.
Investigational
Matched Description: … the treatment of sickle cell disease. ... Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for …
UV1
UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments of the hTERT subunit
Investigational
Matched Description: … of the hTERT subunit ... UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments …
PN0621
PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
Investigational
Fibrinolysin
Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da. Fibrinolysin is used as a...
Investigational
Matched Description: … The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin ... ; the heavy chain has a molecular weight of approximately 57,000 Da. ... Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. …
Varlitinib
Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.
Investigational
Matched Description: … Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients ... Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 ... Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and …
PF-05241328
PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity).
Investigational
Matched Description: … Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not ... under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of …
PTI-801
PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone. It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.
Investigational
Matched Description: … PTI-801 represents a new class of drugs to treat pain. ... It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. ... can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of …
Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was developed using domains of viral structural proteins and a polyprotein protease. Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these...
Investigational
Matched Description: … Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was ... developed using domains of viral structural proteins and a polyprotein protease. ... Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, …
Fucoxanthin
Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green color. Fucoxanthin is investigated for its anti-inflammatory, antinociceptive and anti-cancer effects....
Investigational
Matched Description: … action of fucoxanthin is not fully elucidated. ... an animal model of duodenal, skin, colon and liver cancer. ... of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). …
Pegamotecan
Pegamotecan has been used in trials studying the treatment of Cancer of Stomach, Sarcoma, Soft Tissue, and Gastroesophageal Cancer.
Investigational
Matched Description: … Pegamotecan has been used in trials studying the treatment of Cancer of Stomach, Sarcoma, Soft Tissue …
Aganirsen
Aganirsen is under investigation in clinical trial NCT02947867 (Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG).
Investigational
Matched Description: … at Risk of Developing NVG). ... Aganirsen is under investigation in clinical trial NCT02947867 (Trial of Aganirsen in iCRVO Patients …
BacTRL-spike
BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. The vaccine was developed by Symvivo Corporation. As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to...
Investigational
Matched Description: … BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum ... Trial (NCT04334980) to test the safety and immunogenicity of the vaccine. ... As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled …
Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)-
Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis).
Investigational
Matched Description: … Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid ... )-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of …
Afimoxifene
Afimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia. TamoGel is formulated using Enhanced Hydroalcoholic Gel (EHG) Technology. This technology enables percutaneous delivery of drugs that cannot be delivered orally. It is being developed by...
Investigational
Matched Description: … This technology enables percutaneous delivery of drugs that cannot be delivered orally. ... Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of …
Endothelin-1
Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin).
Investigational
Matched Description: … on Vascular Function - the Role of Endothelin). ... Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation …
RDEA806
RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.
Investigational
Matched Description: … reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of …
(1R,2S)-2-Phenylcyclopropanaminium
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
Experimental
Matched Description: … A propylamine formed from the cyclization of the side chain of amphetamine. ... This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder …
VX-765
VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
Investigational
Matched Description: … VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase ... VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions …
ALT-2074
An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated. BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.
Investigational
Matched Description: … Some indications of efficacy were demonstrated. ... its ability to mimic the function of glutathione peroxidase. ... BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of …
Probiorinse
Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136. This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.
Investigational
Matched Description: … [L16368] This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity ... Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation …
Drinabant
AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.
Investigational
Matched Description: … mechanism of action as rimonabant. ... AVE-1625 is also being developed for the treatment of Alzheimer disease. ... AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same …
Proscillaridin
Proscillaridin is a cardiac glycoside that is derived from plants of the genus Scilla and in Drimia maritima (Scilla maritima). Studies suggest the potential cytotoxic and anticancer property of proscillaridin, based on evidence of the drug potently disrupting topoisomerase I and II activity at nanomolar drug concentrations and triggering cell...
Experimental
Matched Description: … ] and triggering cell death and blocking cell proliferation of glioblastoma cell lines [A27194]. ... Proscillaridin is a cardiac glycoside that is derived from plants of the genus Scilla and in Drimia maritima ... Studies suggest the potential cytotoxic and anticancer property of proscillaridin, based on evidence …
Displaying drugs 10301 - 10325 of 12494 in total